InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development.
Bincovich telling Proactive InnoCan intends to load the produced exosomes with CBD and then will be used in the development of therapy for COVID-19 disease and other indications of the central nervous system.
CSE:INNO
Market: CSE
Market Cap: $33.09 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: Innocan Pharma plans to collaborate with Tel Aviv University...
Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver to bring news the company has entered into a sponsored research agreement with Ramot at Tel Aviv University to collaborate with Tel Aviv University to develop a novel, revolutionary approach to treating...
on 04/23/2020
2 min read
Prev article
2 min read